Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's ...

The appointments come after the company’s controlling shareholder pushed for more changes to revive its success in the weight ...

Novo Nordisk's top shareholder forced through an overhaul of the Wegovy-maker's board at a shareholder meeting on Friday, ...

Novo Nordisk's top shareholder forced through an overhaul of the Wegovy-maker's board at an extraordinary shareholder meeting ...

When Novo Nordisk CEO Mike Doustdar learned in late September that Metsera had accepted a $7.3 billion rival bid from Pfizer ...

After [losing out to Pfizer]( ...

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

Novo Nordisk A/S is tapping the euro bond market with a multi-tranche sale expected to raise about €3.5 billion ($4.1 billion ...